I read this article today in the San Francisco Business Times about approval of the drug, Rituxan, for use against leukemia:

Regulators approved the use of the Genentech Inc. and Biogen Idec treatment Rituxan as part of a combination therapy for chronic lymphocytic leukemia.

South San Francisco-based Genentech, a biotech subsidiary of Swiss drug giant Roche Group, said the Food and Drug Administration approved use of Rituxan in combination with fludarabine and cyclophosphamide for patients starting treatment for CLL as well as for those who have tried other drugs.

Rituxan, an antibody treatment that works with the body’s own immune system, registered sales of $5.9 billion last year. Discovered by Biogen Idec, it also is approved for non-Hodgkin’s lymphoma and rheumatoid arthritis.

Read the entire article by going to: FDA approves Rituxan for form of leukemia.
Feel good and keep smiling! Pat

Leave a Reply